- Home
- INSM
INSM
Insmed Incorporated
as 03-28-2025 4:00pm EST
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 14.3B | IPO Year: | 2000 |
| Target Price: | $95.36 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.92 - $84.91 | Next Earning Date: | 05-08-2025 |
| Revenue: | $363,707,000 | Revenue Growth: | 19.17% |
| Revenue Growth (this year): | 30.31% | Revenue Growth (next year): | 118.39% |
Stock Insider Trading Activity of Insmed Incorporated (INSM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lewis William | INSM | Chair and CEO | Mar 17 '25 | Sell | $76.90 | 25,580 | $1,970,420.71 | 236,661 | |
| Lewis William | INSM | Chair and CEO | Mar 3 '25 | Sell | $78.70 | 25,580 | $1,989,796.50 | 236,661 | |
| Lewis William | INSM | Chair and CEO | Feb 18 '25 | Sell | $80.93 | 25,580 | $2,072,721.15 | 236,661 | |
| Bonstein Sara | INSM | Chief Financial Officer | Feb 18 '25 | Sell | $80.64 | 18,322 | $1,471,394.16 | 118,863 | |
| Bonstein Sara | INSM | Chief Financial Officer | Feb 11 '25 | Sell | $80.00 | 18,321 | $1,465,680.00 | 118,863 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 10 '25 | Sell | $78.24 | 37,828 | $2,973,484.92 | 123,175 | |
| Adsett Roger | INSM | Chief Operating Officer | Feb 10 '25 | Sell | $78.24 | 42,975 | $3,378,066.75 | 172,223 | |
| Lewis William | INSM | Chair and CEO | Feb 5 '25 | Sell | $80.90 | 79,350 | $6,419,415.00 | 236,661 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Feb 5 '25 | Sell | $80.25 | 33,115 | $2,678,924.90 | 123,175 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Feb 5 '25 | Sell | $80.90 | 23,500 | $1,901,150.00 | 120,878 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts
PR Newswire
4 days ago
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
Insider Monkey
11 days ago
Insmed Incorporated (INSM): Among the Best Biotech Stocks to Buy According to Billionaires
PR Newswire
19 days ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MT Newswires
23 days ago
UBS Adjusts Price Target on Insmed to $110 From $105, Maintains Buy Rating
MT Newswires
24 days ago
Insmed Insider Sold Shares Worth $1,989,797, According to a Recent SEC Filing
MT Newswires
a month ago
Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says
MT Newswires
a month ago
RBC Capital Initiates Insmed at Outperform With $100 Price Target
Compare INSM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.